Companies › GeneQuantum Healthcare (Suzhou)
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GQ1005 HER2-targeting antibody-drug conjugate | – | Phase 3 | HER2-positive Breast Cancer | Jan 2027 |
| GQ1010 | – | Phase 1 | Advanced Malignant Solid Tumors | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07673029 | GQ1005 | Phase 3 | HER2-positive Breast Cancer | Oncology | Jan 2027 |
| NCT06464055 | GQ1010 | Phase 1 | Advanced Malignant Solid Tumors | Oncology | May 2028 |
No annotated target.
–
GC Cell Immuneering InxMed (Shanghai) PharmaMar Sellas Life Sciences Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.